← Leaderboards
Joseph F Gera
Sepulveda Research Corporation
$5,390,622
Attributed
$6,054,617
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $693.2K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,054,617 · 5
VA$0 · 1
By mechanism
R01$6,054,617 · 5
I01$0 · 1
Top collaborators
- Alan K Lichtenstein5 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsNeoplastic CellPre-ClinicalResistanceComplexPhosphotransferasesPathway InteractionsSignal TransductionMediatingGrowth FactorProteinsIn VivoTranslationsInternal Ribosome Entry SiteRegulationTumorNutrientSirolimusTumor GrowthGlioblastomaInhibitor/AntagonistLinkBiochemicalProto-Oncogene Proteins C-Akt
Grant awards (35)
Targeting circRNA translation in glioblastoma$313,616
R01 · FY2025 · CA · contact PI
Mechanisms of Resistance to mTOR Targeted Therapies$0
I01 · FY2025 · VA · contact PI
Targeting circRNA translation in glioblastoma$313,616
R01 · FY2024 · CA · contact PI
Mechanisms of Resistance to mTOR Targeted Therapies$0
I01 · FY2024 · VA · contact PI
Mechanisms of Resistance to mTOR Targeted Therapies$0
I01 · FY2023 · VA · contact PI
Co-targeting mTOR and YAP signaling in glioblastoma$320,054
R01 · FY2022 · CA · contact PI
Co-targeting mTOR and YAP signaling in glioblastoma$326,586
R01 · FY2021 · CA · contact PI
Mechanisms of Resistance to mTOR Targeted Therapies$0
I01 · FY2021 · VA · contact PI
Co-targeting mTOR and YAP signaling in glioblastoma$320,662
R01 · FY2020 · CA · contact PI
Mechanisms of Resistance to mTOR Targeted Therapies$0
I01 · FY2020 · VA · contact PI
Co-targeting mTOR and YAP signaling in glioblastoma$311,041
R01 · FY2019 · CA · contact PI
Mechanisms of Resistance to mTOR Targeted Therapies$0
I01 · FY2019 · VA · contact PI
Co-targeting mTOR and YAP signaling in glioblastoma$320,490
R01 · FY2018 · CA · contact PI
Mechanisms of Resistance to mTOR Targeted Therapies$0
I01 · FY2018 · VA · contact PI
Mechanisms of Resistance to mTOR-Targeted Therapies$0
I01 · FY2017 · VA · contact PI
Mechanisms of Resistance to mTOR-Targeted Therapies$0
I01 · FY2016 · VA · contact PI
Dysregulation of mTORC2 in gliomas$229,703
R01 · FY2015 · CA · contact PI
Mechanisms of Resistance to mTOR-Targeted Therapies$0
I01 · FY2015 · VA · contact PI
Dysregulation of mTORC2 in gliomas$222,812
R01 · FY2014 · CA · contact PI
Mechanisms of Resistance to mTOR-Targeted Therapies$0
I01 · FY2014 · VA · contact PI
Regulation of c-myc translation by hnRNP A1: role in multiple myeloma tumor respo$249,066
R01 · FY2013 · CA · contact PI
Dysregulation of mTORC2 in gliomas$215,921
R01 · FY2013 · CA · contact PI
Regulation of c-myc translation by hnRNP A1: role in multiple myeloma tumor respo$264,964
R01 · FY2012 · CA · contact PI
Dysregulation of mTORC2 in gliomas$229,703
R01 · FY2012 · CA · contact PI
Mechanisms of Akt-dependent sensitivity to rapamycin$198,512
R01 · FY2012 · CA · contact PI
Regulation of c-myc translation by hnRNP A1: role in multiple myeloma tumor respo$264,964
R01 · FY2011 · CA · contact PI
Mechanisms of Akt-dependent sensitivity to rapamycin$198,512
R01 · FY2011 · CA · contact PI
Regulation of c-myc translation by hnRNP A1: role in multiple myeloma tumor respo$273,159
R01 · FY2010 · CA · contact PI
Mechanisms of Akt-dependent sensitivity to rapamycin$204,651
R01 · FY2010 · CA · contact PI
Regulation of c-myc translation by hnRNP A1: role in multiple myeloma tumor respo$275,837
R01 · FY2009 · CA · contact PI
Mechanisms of Akt-dependent sensitivity to rapamycin$204,651
R01 · FY2009 · CA · contact PI
Mechanisms of AKT-dependent sensitivity to rapamycin$194,906
R01 · FY2008 · CA · contact PI
Mechanisms of AKT-dependent sensitivity to rapamycin$194,906
R01 · FY2007 · CA · contact PI
Mechanisms of AKT-dependent sensitivity to rapamycin$200,727
R01 · FY2006 · CA · contact PI
Mechanisms of AKT-dependent sensitivity to rapamycin$205,558
R01 · FY2005 · CA